Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REST: Multi-antigen Specific Lymphocytes for Solid Tumors
NCT02789228Phase 1Active, not recruiting
- Sponsor
- Children's National Research Institute
- Start
- Oct 2016
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor (2 arms), sponsored by Children's National Research Institute. Primary endpoint: Incidence of Product-Emergent Adverse Events at 28 days. Started Oct 2016; status: active, not recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02789228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789228.